• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Y-Mabs Therapeutics Inc (NQ: YMAB )

    10.41 +0.31 (+3.07%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 253,872
    Open 10.09
    Bid (Size) 4.180 (2)
    Ask (Size) 16.68 (2)
    Prev. Close 10.10
    Today's Range 9.930 - 10.49
    52wk Range 5.290 - 20.90
    Shares Outstanding 44,789,076
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement
    Via Benzinga
    Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
    Via Benzinga

    Performance

    YTD
    +51.53%
    +51.53%
    1 Month
    -29.99%
    -29.99%
    3 Month
    -24.24%
    -24.24%
    6 Month
    -14.81%
    -14.81%
    1 Year
    +91.36%
    +91.36%

    More News

    Read More
    Examining the Future: Y-mAbs Therapeutics's Earnings Outlook
    Via Benzinga
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Via Benzinga
    Navigating 8 Analyst Ratings For Y-mAbs Therapeutics
    Via Benzinga
    Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
    Via Benzinga
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Earnings Outlook For Y-mAbs Therapeutics
    Via Benzinga
    Why Y-mAbs Therapeutics Stock Got Mashed on Monday
    Via The Motley Fool
    YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
    From Pomerantz LLP
    Via GlobeNewswire
    MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
    Via Benzinga
    YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
    Via Investor's Business Daily
    Micro Marvel - Y-Mabs Therapeutics
    Via Talk Markets
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Earnings Scheduled For November 13, 2023
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.